Skip to main content

PERSPECTIVE article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1474798

Erbin: An important therapeutic target for blocking tumor metastasis

Provisionally accepted
Tingting Qiu Tingting Qiu 1Liquan Tan Liquan Tan 1Jialong Yan Jialong Yan 2Qunli Luo Qunli Luo 1*
  • 1 The Affiliated Nanhua Hospital, Hengyang Medical School,, University of South China, Hengyang, Hunan Province, China
  • 2 The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China

The final, formatted version of the article will be published soon.

    Erbin is an adapter protein that interacts with the v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) in epithelial cells. Erbin plays an important role in various signaling pathway including cell proliferation, apoptosis, and autophagy. Additionally, Erbin implicates in the pathogenesis and progression of sepsis and various cancer, including breast cancer, acute myeloid leukemia (AML), hepatocellular carcinoma (HCC) and colorectal cancer (CRC). A recent study shows that loss of Erbin increases the release of acyl-carnitine (Acar) through abolishing interaction with prothrombotic protein ESAM, that promote mitochondrial oxidative phosphorylation in B cells, and ultimately suppresses lung metastasis of CRC. Accordingly, Erbin provides us a new potential treatment of tumor metastasis.

    Keywords: Erbin, tumor, metastasis, antitumor immunity, platelets

    Received: 02 Aug 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Qiu, Tan, Yan and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qunli Luo, The Affiliated Nanhua Hospital, Hengyang Medical School,, University of South China, Hengyang, 421001, Hunan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.